alexa A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.


Journal of Multiple Sclerosis

Author(s): Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A,

Abstract Share this page

Abstract BACKGROUND: Interferon beta 1b (Betaferon) and 1a (Avonex) were licensed in Italy for treating relapsing-remitting multiple sclerosis in February 1996 and August 1997, respectively. OBJECTIVES: To evaluate the effectiveness of these agents on the basis of clinical experience in northern Italian multiple sclerosis centres. DESIGN: Clinical data on patients with relapsing-remitting multiple sclerosis were collected on an appropriate form from 65 centres in northern Italy. Intention to treat analysis was not possible, so patients who discontinued treatment (drop-outs) and who continued treatment (treated) were analysed separately. The main outcome measures were annual relapse frequency, number of relapse-free patients, mean change in extended disability status scale score (EDSS), and number of patients who worsened. RESULTS: 1481 patients were included; 834 were treated with Betaferon and 647 with Avonex for mean periods of 21.4 and 12.0 months, respectively. Basal EDSS was 2.37 and 2.17, respectively, and relapse frequency was 1.62 and 1.45. The annual relapse rate decreased by more than 60\% with Betaferon and 55\% with Avonex. The proportions of relapse-free, improved, and worsened patients were similar in the two groups. More patients interrupted treatment with Betaferon (41.1\%) than with Avonex (15.3\%); such patients showed more active disease at baseline and during treatment. The incidence of side effects was higher in Betaferon treated patients. CONCLUSIONS: The effectiveness of Betaferon and Avonex is confirmed. There was a more marked effect than expected from the experimental trial results. This might reflect differences in inclusion criteria, or, more likely, loss of drop-outs, favouring selective retention of responders.
This article was published in J Neurol Neurosurg Psychiatry and referenced in Journal of Multiple Sclerosis

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ildiko Molnar
    The role of tissue-specific type 2 5’-deiodinase enzyme activities in Graves’ orbitopathy and systemic sclerosis: a new candidate in thyroid autoimmunity
    PDF Version
  • Pauline Korukundo
    PPT Version | PDF Version
  • Erinç Uludamar
    PPT Version | PDF Version
  • Sergey Suchkov
    Translational tools as applicable to autoimmune disorders: antibody-proteases as a generation of highly informative and unique biomarkers to monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS)
    PPT Version | PDF Version
  • Miriam Furst-Yust
    PPT Version | PDF Version
  • Ahmed G Hegazi
    Cytokines pattern of multiple sclerosis patients treated with Apitherapy
    PPT Version | PDF Version
  • Xuejun H Parsons
    Direct conversion of pluripotent human embryonic stem cells into functional human neuronal or cardiomyocyte cell therapy derivatives for regenerative medicine
    PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version